Biologic targets for therapeutic intervention in endometrioid endometrial adenocarcinoma and malignant mixed müllerian tumors
Authors:
- Laurel W. RiceLRLaurel W. Rice
- Rebecca L. StoneRSRebecca L. Stone
- Miaohou XuMXMiaohou Xu
- Mary GalganoMGMary Galgano
- Mark H. StolerMSMark H. Stoler
- Elise N. EverettEEElise N. Everett
- Amir A. JazaeriAJAmir A. Jazaeri
- 1 April 2006
- journal article
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 194 (4) , 1119-1126
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Phase III Trial of Doxorubicin With or Without Cisplatin in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2004
- Loss of PTEN expression is associated with metastatic disease in patients with endometrial carcinomaCancer, 2002
- Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinaseNature, 2000
- Altered PTEN Expression as a Diagnostic Marker for the Earliest Endometrial PrecancersJNCI: Journal of the National Cancer Institute, 2000
- Biomarkers in the endometriumJournal of Cellular Biochemistry, 1995
- Prognostic Factors for Malignant Mixed Mullerian Tumors of the UterusInternational Journal of Gynecological Pathology, 1990
- Clinicopathologic analysis of uterine malignant mixed müllerian tumorsGynecologic Oncology, 1989
- Features associated with survival and disease-free survival in early endometrial cancerAmerican Journal of Obstetrics and Gynecology, 1989
- Surgical pathologic spread patterns of endometrial cancer: A gynecologic oncology group studyCancer, 1987
- Prognostic factors and sites of failure in figo Stage I, Grade 3 endometrial carcinomaGynecologic Oncology, 1987